Truist Financial Corp Purchases 864 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Truist Financial Corp boosted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 1.9% during the fourth quarter, Holdings Channel reports. The firm owned 46,539 shares of the exchange traded fund’s stock after purchasing an additional 864 shares during the quarter. Truist Financial Corp’s holdings in SPDR S&P Biotech ETF were worth $6,552,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Morgan Stanley lifted its position in SPDR S&P Biotech ETF by 34.3% during the fourth quarter. Morgan Stanley now owns 15,424,655 shares of the exchange traded fund’s stock valued at $2,171,483,000 after purchasing an additional 3,939,244 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in SPDR S&P Biotech ETF by 514.1% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 14,334,000 shares of the exchange traded fund’s stock valued at $2,017,941,000 after buying an additional 12,000,000 shares during the last quarter. Wells Fargo & Company MN increased its holdings in SPDR S&P Biotech ETF by 159.4% during the fourth quarter. Wells Fargo & Company MN now owns 2,998,830 shares of the exchange traded fund’s stock valued at $422,175,000 after buying an additional 1,842,571 shares during the last quarter. LPL Financial LLC increased its holdings in SPDR S&P Biotech ETF by 31.5% during the fourth quarter. LPL Financial LLC now owns 599,865 shares of the exchange traded fund’s stock valued at $84,449,000 after buying an additional 143,785 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of SPDR S&P Biotech ETF by 3.3% during the 4th quarter. Squarepoint Ops LLC now owns 261,711 shares of the exchange traded fund’s stock valued at $36,844,000 after buying an additional 8,246 shares in the last quarter.

XBI opened at $131.75 on Thursday. SPDR S&P Biotech ETF has a fifty-two week low of $79.19 and a fifty-two week high of $174.79. The firm’s fifty day moving average is $143.67 and its 200 day moving average is $137.38.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: What is a capital gains distribution?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.